Market News AIOpen the app

Silexion Therapeutics can stay on the Nasdaq after getting approval, as long as it meets certain money rules.

TroubleRead the original at SEC EDGAR
Bad for SLXN

Silexion can stay listed for now, but must secure $2.5 million after costs and finish an offering of at least $5 million. It must also meet the $1 share-price test, and missing another Nasdaq rule can mean immediate delisting.

SLXN · Silexion Therapeutics Corp

AI read · Bad for SLXN

The AI's read

This gives Silexion a chance to keep trading on Nasdaq. Yet it has to raise money twice, keep its closing share price at or above $1 for 10 trading days, and meet several deadlines. Missing a requirement could end its Nasdaq listing, so the relief is limited.

Get alerts for SLXN

Follow Silexion Therapeutics Corp (SLXN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SLXN
Free on the App Store and Google Play, or on the web.